RxDoctor Payments Data

Linda Davis, MD

Family Medicine · Mission Viejo, CANPI 1871664987

Payments from drug & device makers

$171,345in general payments, 2019–2025

Across 746 payments — averaging $229.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$104K
  • Eli Lilly$29K
  • AbbVie$23K
  • Amgen$8K
  • Teva Pharmaceuticals USA, Inc.$4K
  • AstraZeneca$1K
  • plus $2K from 26 others
$13,125in research payments, 2019–2025

Across 1 payment — averaging $13,125 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$13K

What the payments were for

  • Consulting fees$60,52935%
  • Speaking & faculty fees$79,02546%
  • Grants$1290%
  • Travel & lodging$19,01611%
  • Food & beverage$11,6047%
  • Education$1,0421%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,345 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$59,403
Medicare patients
121
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$64,034
TrulicityDulaglutide16$23,799
EliquisApixaban16$14,617
BelsomraSuvorexant31$13,355
FarxigaDapagliflozin Propanediol13$11,972
VascepaIcosapent Ethyl11$11,574
XareltoRivaroxaban12$7,044
JanumetSitagliptin Phos/Metformin Hcl11$6,108
SynthroidLevothyroxine Sodium49$5,042
Breo ElliptaFluticasone/Vilanterol12$4,168
Janumet XrSitagliptin Phos/Metformin Hcl12$3,351
Fluticasone Propionate31$2,136
Lidocaine11$2,037
Gabapentin49$1,612
Lubiprostone19$1,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$104,418$87,83374 claims
MerckBelsomra, Janumet, Janumet Xr$62$22,81554 claims
PfizerEliquis$90$14,61716 claims
AstraZenecaFarxiga$1,156$11,97213 claims
AbbVieSynthroid$22,685$5,04249 claims
GSKBreo Ellipta$25$4,16812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →